Arrowhead reports lower pancreatitis rates, early cholesterol drug results (ARWR:NASDAQ)
· seekingalpha.com
Arrowhead’s plozasiran cut pancreatitis rates 78% in late-stage studies.
Worsening blood-sugar control occurred in 14% of plozasiran recipients versus 8.7% on placebo. Overall health problems occurred at similar rates in both groups,...